Presentation Details Conference: BTIG Virtual Biotechnology Conference Format: Fireside chat with covering analyst, Kaveri Pohlman, Ph.D. Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer Date: August 5, 2024 Time: 2:00 p.m. ET Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds deri ...

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck's addition will be effective today when the U.S ...

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck's addition will be effective today when the U.S ...

Shattuck Labs, Inc. (STTK) announced updated interim data from the phase IB dose expansion study of lead candidate SL-172154, in combination with azacitidine, in frontline higher-risk myelodysplastic syndromes (HRMDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients. SL-172154 is an investigational agonist redirected checkpoint fusion protein, designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor to bolster an anti-tumor immune res ...

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that the U.S. FDA has granted orphan drug designation (ODD) to lead clinical candidate SL172154 for the treatment of AML. "AML patients have few options for treatment and a poor prognosis. ...

"AML patients have few options for treatment and a poor prognosis. FDA's decision to grant orphan drug designation to SL-172154 highlights the urgent need for new treatment options," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "This is an important first step in our progression to later-stage clinical studies, and we look forward to presenting additional data from the Phase 1B dose expansion clinical trial of SL-172154 with azacitidine in frontline higher-risk myelodysplastic sy ...

Shattuck Labs, Inc. (STTK) has been on a downward spiral lately with significant selling pressure. After declining 19.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

Financial Data and Key Metrics Changes - As of September 30, 2023, the company reported cash and cash equivalents and investments of $101.1 million [15] - Research and development expenses for Q3 2023 were $24.2 million, an increase from $18.9 million in Q3 2022 [15] - General and administrative expenses decreased to $5.1 million in Q3 2023 from $6.6 million in Q3 2022 [49] - The net loss for Q3 2023 was $27.5 million, or $0.65 per share, compared to a net loss of $24.6 million, or $0.58 per share, in Q3 2022 [49] Business Line Data and Key Metrics Changes - The ongoing Phase 1B trial of SL-172154 in combination with PLD for platinum-resistant ovarian cancer has enrolled 16 patients, with 11 being evaluable for efficacy [70][90] - In the Phase 1A/B trial for AML and higher-risk MDS, 37 patients have received SL-172154, with one complete response observed in a TP53 mutant higher-risk MDS patient [105][107] Market Data and Key Metrics Changes - The company is focusing on high unmet medical needs in the oncology space, particularly in AML and higher-risk MDS, where there is a significant opportunity for accelerated development [71] - The competitive landscape for CD47 inhibitors has evolved, with several agents facing challenges, which may provide an opportunity for SL-172154 to differentiate itself [110] Company Strategy and Development Direction - The company aims to leverage its unique mechanism of action with SL-172154, which combines CD47 inhibition with CD40 activation, to improve response rates and durability in patients [88][77] - There is a focus on completing enrollment in ongoing trials and presenting data at upcoming conferences, including the ASH Annual Meeting [16][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the financial position, stating that current cash reserves are sufficient to fund operations through the end of 2024 [93] - The management team is optimistic about the potential of SL-172154 to meet unmet medical needs and is encouraged by the early clinical data [101][77] Other Important Information - The company plans to present complete data from the dose escalation portion of the trial at the ASH meeting and share initial data from frontline cohorts [48][50] - The safety profile of SL-172154 has been acceptable, with infusion-related reactions being the most common adverse event [90] Q&A Session Summary Question: Can you provide more detail about the baseline characteristics of patients in the PROC study? - The majority of patients (88%) had failed frontline platinum-containing regimens, with 100% having received platinum and 56% having received bevacizumab [51] Question: What is the expected response rate for the PLD plus SL-172154 combination? - A response rate in excess of 25% in an all-comer PROC setting could be meaningful, especially if accompanied by a duration of response exceeding five months [140] Question: Are there plans to use biomarker analysis in the PLD combo trial? - The company is collecting various biomarker data to analyze differences in responders and nonresponders [60] Question: What are the expectations for the TP53 mutant AML cohort? - There is potential for an accelerated path if the complete response rate exceeds 40%, which would be a good indicator for duration of response [112] Question: How does SL-172154 compare to other CD47 inhibitors in terms of efficacy? - The company is looking to demonstrate the impact of CD40 ligand on efficacy in responding patients, especially in the context of evolving competition in the CD47 space [95]